Veterinary Tuberculosis Vaccine Market, by Type (Live Attenuated, Inactivated), by Route of Administration (Sub-cutaneous, Intramuscular, Oral), by Animal Type (Cattle, Dogs, Cats, Others), and by Region (North America, Latin America, Europe, Asia Pacific
Description
Veterinary Tuberculosis Vaccine Market, by Type (Live Attenuated, Inactivated), by Route of Administration (Sub-cutaneous, Intramuscular, Oral), by Animal Type (Cattle, Dogs, Cats, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Tuberculosis (TB) is considered a reemerging, infectious granulomatous disease in animals and people caused by acid-fast bacilli of the genus Mycobacterium. Although commonly considered as a chronic, debilitating disease, TB occasionally assumes an acute, rapidly progressive course. The disease affects practically all species of vertebrates. The widespread occurrence of multidrug-resistant (MDR) strains and extensively drug-resistant (XDR) strains of M tuberculosis is of concern to clinicians and public health and regulatory officials involved in the control of the disease. Bovine TB is still a significant zoonosis in non-industrialized countries of the world. Signs and lesions are generally similar in the various species. The main types of M tuberculosis complex (mammalian tubercle bacilli) recognized are M tuberculosis, M canettii, M bovis, M caprae, M pinnipedii, M microti, M mungi, and M africanum. The M avium complex includes M avium avium (avian tubercle bacilli), M avium hominissuis (isolated from people, swine, and other mammals), and M intracellular.
Market Dynamics
Increasing undergoing trial for vaccination is expected to fuel growth of the global veterinary tuberculosis vaccine market over the forecast period.
For instance, according to a report published by Multidisciplinary Digital Publishing Institute in June 2020, BCG (Danish) vaccine type is administered by intramuscular to badgers for the prevention of tuberculosis. According to the same source, heat-inactivated Mycobacterium bovis vaccine (HIMB) is administered by intramuscular method to goats for the prevention of tuberculosis
Furthermore, increasing awareness programs for veterinary tuberculosis by government authorities is expected to drive growth of the global veterinary tuberculosis vaccine market over the forecast period.
For instance, on November 16, 2021, The Welsh Government, U.K. announced the Tuberculosis (TB) Eradication Programme. This program's goal was to offer a TB testing programme in Wales, U.K., in order to further lower the danger of the spread of TB. The Welsh Government, U.K. has advised to make informed purchase selections and to disclose TB information about any cattle they seek to sell. Payments for animals that were killed due to TB, to make sure the method is just and appropriate and takes into account the available funding.
Key features of the study:
Tuberculosis (TB) is considered a reemerging, infectious granulomatous disease in animals and people caused by acid-fast bacilli of the genus Mycobacterium. Although commonly considered as a chronic, debilitating disease, TB occasionally assumes an acute, rapidly progressive course. The disease affects practically all species of vertebrates. The widespread occurrence of multidrug-resistant (MDR) strains and extensively drug-resistant (XDR) strains of M tuberculosis is of concern to clinicians and public health and regulatory officials involved in the control of the disease. Bovine TB is still a significant zoonosis in non-industrialized countries of the world. Signs and lesions are generally similar in the various species. The main types of M tuberculosis complex (mammalian tubercle bacilli) recognized are M tuberculosis, M canettii, M bovis, M caprae, M pinnipedii, M microti, M mungi, and M africanum. The M avium complex includes M avium avium (avian tubercle bacilli), M avium hominissuis (isolated from people, swine, and other mammals), and M intracellular.
Market Dynamics
Increasing undergoing trial for vaccination is expected to fuel growth of the global veterinary tuberculosis vaccine market over the forecast period.
For instance, according to a report published by Multidisciplinary Digital Publishing Institute in June 2020, BCG (Danish) vaccine type is administered by intramuscular to badgers for the prevention of tuberculosis. According to the same source, heat-inactivated Mycobacterium bovis vaccine (HIMB) is administered by intramuscular method to goats for the prevention of tuberculosis
Furthermore, increasing awareness programs for veterinary tuberculosis by government authorities is expected to drive growth of the global veterinary tuberculosis vaccine market over the forecast period.
For instance, on November 16, 2021, The Welsh Government, U.K. announced the Tuberculosis (TB) Eradication Programme. This program's goal was to offer a TB testing programme in Wales, U.K., in order to further lower the danger of the spread of TB. The Welsh Government, U.K. has advised to make informed purchase selections and to disclose TB information about any cattle they seek to sell. Payments for animals that were killed due to TB, to make sure the method is just and appropriate and takes into account the available funding.
Key features of the study:
- This report provides an in-depth analysis of the global veterinary tuberculosis vaccine market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global veterinary tuberculosis vaccine market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Merck KGaA, Colorado Serum Company, CZ Vaccines (Zendal), and Zoetis Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global veterinary tuberculosis vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global veterinary tuberculosis vaccine market
- Global Veterinary tuberculosis vaccine market, By Type:
- Live Attenuated
- Inactivated
- Global Veterinary tuberculosis vaccine market, By Route of Administration:
- Sub-cutaneous
- Intramuscular
- Oral
- Global Veterinary tuberculosis vaccine market, By Animal Type:
- Cattle
- Dogs
- Cats
- Others
- Global Veterinary tuberculosis vaccine market, By Region:
- North America
- By Country
- U.S.
- Canada
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Region/Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Merck KGaA *
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Colorado Serum Company
- CZ Vaccines (Zendal)
- Zoetis Inc.
Table of Contents
197 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route Of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Regulatory Scenario
- Key Highlights
- Research and Development Collaboration, Mergers, and Acquisitions
- PEST Analysis
- Pipeline Analysis
- Epidemiology
- 4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market– COVID-19 Impact Analysis
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the market
- 5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Bronchodilators
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Beta 2-Agonists
- Anticholinergics
- Theophyllines
- Phosphodiesterase Type 4 Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Steroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- 6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route Of Administration, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Inhalation
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- 7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- 8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region, 2017 – 2030, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 – 2030, (US$ Million)
- North Africa
- Central Africa
- South Africa
- 9. Competitive Landscape
- Heat Map Analysis
- Company Profiles
- AstraZeneca Plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Orion Corporation
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan N.V.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sunovion Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- CHIESI Farmaceutici SpA
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- 10. Section
- References
- Research Methodology
- About Us and Sales Contact
- *Browse 26 market data tables and 32 figures on "Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market” - forecast to 2030
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
